Furthermore, mutations beyond the primary BCR::ABL1 fusion gene, particularly in genes such as ASXL1, RUNX1, and TP53, complicate the molecular landscape of CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.